title: Gene expression profiling of a hypoxic seizure model of epilepsy suggests a role for mTOR and Wnt signaling in epileptogenesis.
abstract: Microarray profiling was used to investigate gene expression in the hypoxic seizure model of acquired epilepsy in the rat, with the aim of characterizing functional pathways which are persistently activated or repressed during epileptogenesis. Hippocampal and cortical tissues were transcriptionally profiled over a one week period following an initial series of seizures induced by mild hypoxia at post-natal day 10 (P10), and the gene expression data was then analyzed with a focus on gene set enrichment analysis, an approach which emphasizes regulation of entire pathways rather than of individual genes. Animals were subjected to one of three conditions: a control with no hypoxia, hypoxic seizures, and hypoxic seizures followed by treatment with the AMPAR antagonist NBQX, a compound currently proposed to be a modulator of epileptogenesis. While temporal gene expression in the control samples was found to be consistent with known processes of neuronal maturation in the rat for the given time window, the hypoxic seizure response was found to be enriched for components of the PI3K/mTOR and Wnt signaling pathways, alongside gene sets representative of glutamatergic, synaptic and axonal processes, perhaps regulated as a downstream consequence of activation of these pathways. Wnt signaling components were also found enriched in the more specifically epileptogenic NBQX-responsive gene set. While activation of the mTOR pathway is consistent with its known role in epileptogenesis and strengthens the case for mTOR or PI3K pathway inhibitors as potential anti-epileptogenic drugs, investigation of the role of Wnt signaling and the effect of appropriate inhibitors might offer a parallel avenue of research toward anti-epileptogenic treatment of epilepsy.
authors.affiliation: Translational and Experimental Medicine, Sanofi Cambridge Research Center, Cambridge, Massachusetts, United States of America.
authors.forename: Joachim
authors.initials: J
authors.lastname: Theilhaber
authors.forename: Sanjay N
authors.initials: SN
authors.lastname: Rakhade
authors.forename: Judy
authors.initials: J
authors.lastname: Sudhalter
authors.forename: Nayantara
authors.initials: N
authors.lastname: Kothari
authors.forename: Peter
authors.initials: P
authors.lastname: Klein
authors.forename: Jack
authors.initials: J
authors.lastname: Pollard
authors.forename: Frances E
authors.initials: FE
authors.lastname: Jensen
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D020869:Gene Expression Profiling; D018507:Gene Expression Regulation, Developmental; D000860:Hypoxia / Q000150:complications / Q000235:genetics* / Q000473:pathology; D055495:Neurogenesis / Q000187:drug effects / Q000235:genetics; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009836:Oligodendroglia / Q000378:metabolism / Q000473:pathology; D009928:Organ Specificity / Q000187:drug effects / Q000235:genetics; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D012640:Seizures / Q000150:complications / Q000235:genetics* / Q000473:pathology; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*; D013997:Time Factors; D060449:Wnt Signaling Pathway / Q000187:drug effects
chemical_list: D015415:Biomarkers; D011810:Quinoxalines; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D058570:TOR Serine-Threonine Kinases